Thank you, Rose. Today, I’ll give you an overview of the commercial efforts to date; I want to talk first about the market trends that favor Afrezza and most importantly where our current prescriptions have been trending. I’m really impressed that within the first three to four weeks of our sales force being out there, we’ve been able to stem a nine-month decline that’s been ongoing since September 2015 and stabilize that during the month of July. For those who may or may not know, new technology is giving more transparency on how to treat patients individually and optimally. And what that means is when you think about [indiscernible] system launching around the world [ex-US] as well as the Dexcom FDA hearing last week, which looks like that’ll have a positive outcome, the ability for patients to see their highs and lows on a daily basis every five to 10 minutes is now becoming a reality. That will allow our patients to pursue a next fold here to measure their timing range for tighter control. Patients often struggle with highs and lows of diabetes on a daily basis and we often don’t know what an average is as you look throughout the day. But the new technology that we’ve seen advance over the last one and two years, the patient’s ability to now try to manage their glucose levels in a tighter range is becoming a reality and we are seeing clinical trials continuing to enroll patients with these types of objectives in mind. A product like Afrezza that starts to work in 10 to 15 minutes allows you to see activity pretty quickly when you’re using this technology. The third thing that we see is patient engagement in their health is shifting [indiscernible] and deductible plans continue to become the predominant ways for some of the players, patients are taking a more active role in their health trying to manage their blood glucose as well as the multiple copays in our pocket cost that they have, so we’re seeing continued expansion as this is the number one cost driver for insurers that they continue to launch more and different and new programs to help these patients manage their glucose and measure their daily lifestyle behaviors. Now, I want to bridge into a question that we often get which is around our target market and how are we going to go about the segmentation of the current field footprint. Our focus is on the 6.5 million patients with diabetes, who are on basal plus or minus insulin, the majority of whom these patients are not at goal. So if you look on the left side of this chart, Type 1 diabetics are approximately 1.25 million, Type 2 basal who are not on Bolus is roughly 2.75 million and Type 2 basal Bolus patients who are on basal Bolus regimen is almost 3 million. This is how you get to the 6.5 million patients with diabetes. Of these, you would see monthly prescription trend of approximately 1.7 million prescriptions in a given month and targeting this population. Our current field footprint is about 1.4 million of those prescriptions. We’re targeting about 75% of the insulin market with our current sales structure. The next question I often get that I think is important for everyone is around our price point and the cost of Afrezza. Afrezza, as you know, is reimbursed across all payor segments from commercial to Medicare, but the rapid-acting analog price increases over the last three years has really started to create challenges in the marketplace. You see in the box below the WAC price of rapid-acting analog has increased 80% since July 2013. So today, when you look at the price of Afrezza since we got approved, the price of Afrezza is cheaper to insulin as we now know the average price of insulin per day is approximately $19 and if you look at the recent launch of our titration pack, we’ve priced it at $3 a unit or cartridge and so when you look at $3 a cartridge and a patient was to take three cartridges a day, you could be looking at a price point of $9 a day. If they were to take six cartridges either because they need additional dosing or follow up dosing, you’ll be looking at a price point of $18 a day. So the current WAC price of Afrezza is not the challenge. The challenge is payors are trying to control their cost and so they’re being more restricted on formularies and that’s often why we’re seeing patients may need to switch between a Humalog and NovoLog that they’re trying to manage the cost trends especially in this category. Going to the next slide, we were able to transition our inventory during the week of July 25. MannKind will now book 100% of Afrezza revenue pretty much starting in the month of August, once divested remaining supplies, the pharmacy shelves will run out of stock. We know the majority of the wholesalers are no longer stocking Sanofi products, so we’re relatively confident that every product shipping at a wholesaler is from this day forward will be branded MannKind. You see here the four NDC that now match to Sanofi, old NDC and the MannKind new NDC. These were important to keep consistent as well the price point to minimize any distractions in the marketplace. We did launch a new product with the titration pack which I’ll talk about further and that’s the new NDC. As you may or may not be aware, during these transitions, there’s multiple computer systems that feed into each other across the supply chain that have to update, some of them update in one day, some of them update over three to seven days. So we knew there were stock outs last week in a couple geographic markets or wholesalers, majority of those issues should be resolved and our wholesalers today have done essential distribution which means within one day a pharmacy should be able to order and stock Afrezza. They will have to order in some cases, in other cases they’ll stock it when a patient actually fills the first prescription, they will continue to keep it in stock. Those are the initiatives that we’re currently working on to make sure that we minimize any patient disruption at the local level. The next question we get is around our branding campaign. It’s important to know that MannKind was able to develop and launch a new brand campaign and move away from the Sanofi’s surprise of insulin. We’re proud to announce that our focus is not on the inhalation aspects of Afrezza, but it’s much more on the insulin and outsulin component. And so you see here just a brief snapshot of what that would look like and how we talk about insulin is how quickly it acts and we talk about – how quickly it disappears. We really want to spark a dialogue in the marketplace around the insulin and outsulin components of insulin and how Afrezza plays a new role within the treatment of these patients, highlighting the PK profile as we see it today. There is obviously a lot more behind the campaign, but I want you to be rest assured the feedback from patients and physicians has been extremely positive. Next, I want to talk about some of the new initiatives which I believe are critical as you look at how we relaunch this product. First and most important is MannKind Cares. This is a patient reimbursement hub that is administered at the physician office and because we know Afrezza will require prioritization in certain cases and most cases, this is meant to streamline that process so the offices can get a prioritization approval within one to three days. Upon approval, the patients will be enrolled in an adherence program and one of the things we did learn is a lot of patients were struggling with getting access to Afrezza at the pharmacy and/or titrating in their early weeks of treatment. This program is designed to ensure patients are titrating appropriately, reaching their goals and getting products filled as quickly as possible. There are numerous details behind this program I’ll not highlight here, but for simplicity of our shareholders, you should rest assured that we want to make sure that patient reimbursement prioritization within our target audience is something that we minimize, this is the program we’ve talked to many of our key customers about, they’re excited to use it and we believe this was streamlined, the prioritization process and getting approval for patients quickly. The next program which I’ll share with you which is our earliest indicator of our weekly prescriptions is our Afrezza CoPay card program. This is administered by McKesson and we moved it and launched it the last week of July to now $15 copay per month and we’re hoping [indiscernible] on a couple other basals at about $15 per month and we’re hopeful that doctors will take a patient, simplify their life to a basal one shot a day along with Afrezza for $30 a month on the commercial side of the patients – commercially insured patients. And we really try to streamline this to make it easy $15 a month consistently, so there’s not a lot of confusion between the different types of programs out there. The other thing you’ll hear us launch which is just a short term pilot is a voucher program. This voucher program will be good for one month sample of the titration pack and this is meant to drive demand pull through to the wholesale channel to ensure the local pharmacies are stocking it as well as a supplement for our current sample program. Our current sample program as we’ve stated previously was four units sample packs which we know are suboptimal for the majority of patients to reach their goals in the first seven days of treatment. This titration pack will allow patients to have enough drug to get through the titration phase or deal with insurance as well as launch our new sample program in late September or early October. The final one we talked about is the titration pack and this one is really meant to solve several problems as we know patients couldn’t always get the right number of boxes or the box configuration at the pharmacy. The pharmacist couldn’t always figure out exactly which box to pick when the doctor prescribed it and the doctor wasn’t sure which box to prescribe based on how many units the patient was using. And so there was a lot of confusion when we looked back at the data and the market research. And this new titration box literally will simplify the process for the doctor, the patient and the pharmacy by allowing them to have a 30-day supply of titration of 180 cartridges which will provide them enough units to combine to get the 4, 8, 12 or 24 units in a dose to ensure they have an optimal experience and don’t run short within a given month. Another question we get is around our direct to consumer and raising consumer awareness. And I want you to know we’re not ignoring the feedback from our shareholders, but it is important to understand the difference between direct to consumer which is a med, a mass, broad advertising campaign to people who may not be a target audience versus a direct to patient effort who are in that 6.5 million number I highlighted earlier. So we have several initiatives on track to launch starting in September which will be our first consumer print ad you will start to see out there in mid to late September pop up in some journals. We are updating our consumer website to reflect the new marketing campaign and once that’s updated we will kick off our new digital campaign with a few partners and you’ll start to see that pop up again in mid September at the latest. And then we have identified several direct mail opportunities that we compile and see targeting patients directly in the mail. As you know, the average age of a Type 2 or Type 1 patient could be in the 45 to 55 range and sometimes direct mails are better way to go as opposed to digital for younger audience. Either way, we will have lots of data coming out in Q3 that would continue to fine tune our direct to patient efforts. And then finally we’re looking at community events and patient conferences. We know there’s many conferences happening in Q4 and Q3. We plan to be present at those events; we were already present at several physician conferences over the last few weeks as well as some upcoming ones in Florida and Texas. So we’re going after the patients directly as well as trying to be present where there are local and regional physician conferences. I will note on the consumer side we will see well over the ability to reach in the hundreds of thousands of consumers. So if you ask me to quantify how many patients are we looking at with our efforts, it’s in that vicinity. So the next question which I think is important to all of us is what are the early indicators and what can you tell us how we’re doing to date. And I want to preface this by saying these are as early as you could possibly want. It’s difficult to make projections off of literally weeks and days of data. However, I think it’s important to be transparent with the market about what we’re seeing and why we are optimistic around our changing curve and what we see in the future. So number one is samples. So we know that samples were really not out there in the channel over the last six months in a meaningful way. We were out there. We just launched our sample program two weeks ago and in the first two weeks we had well over 300 sample requests amongst our targets. Those just shipped literally late last week or early this week, people will be receiving them and so all the prescription trends that we’ve seen over the last few weeks have been without samples in the marketplace for a large majority of our customers. Now that they have samples we know several doctors have said I want samples and copays in my office, once I have them I’ll start to prescribe further again. So those products are – both of those are starting to hit doctors’ offices this week and next week as well as last week. The next two early indicators are the number of patients who enroll in our copay card program which is currently only done via web, the physical card will be dropped in the offices starting this week and then the next one is once they register on the web, how many of them are redeemed. And I’ll share that data with you in a moment because those are the earliest indicators that we get on a daily basis that I think are important for you to see. The next two aspects that we look at are NRx trends which we will try to be transparent and disclose those in some form or fashion as we fine tune this. But we know we’ve gone roughly from 84 to 116 new Rxs in the first few weeks and that trend should continue and that’s despite some of the stock outs that I described earlier around the inventory transition. And the next metric that we look at is around new writers and trialist. And in that number, we’ve seen almost 300 new prescribers in Q2 alone who [now bring] Afrezza in 2016, commemorate Afrezza for the first time. So we are seeing broad trialist happen and we know we’ll continue to cultivate that as we go into Q3 going forward. And on the flip side, these are the measurable indicators, we have qualitative indicators. And what I mean by that is things where we’re out there talking to doctors, the feedback anecdotally from the field, the speaker program and interactions we’ve had and those are very strong as well. So when you think about speaker training and programs, we just kicked off our speaker program literally this week will be. It will be launching, but we had our speaker training last week and we had significant number of attendees show up last minute. We didn’t have anyone not show up and the feedback and the questions are really important to have the dialogue and they left trained and ready to go and excited and I think that gives us some minimum as well as we go into Q3 and Q4. And then the next to around field sales, nurse educators are out there as well, the manager feedback where they’re doing field rides and engaging in the thought leaders around the local markets. And all of that feedback is also coming consistently positive and welcoming, people are generally happy to see MannKind come out and show up and know that the product will still be available. And as you could imagine, there’s a lot of resistance – a lot of our customers literally thought the product was coming off the market and was no longer going to be supplied. So when you look at the decline in prescriptions from January through June, a lot of that was the result of people not believing we were going to be around in July and they thought once the Sanofi inventory ran out that was it, the product will no longer be available. So as a result of that, they stopped initiating new patients back in Q1 and Q2. Now that we’ve been out there for almost a month creating our second and third visits, doctors are remaining confident, they’re starting to see our samples and copays. We expect this trend to change quickly around the feedback and availability of Afrezza amongst our top prescribers. And then finally, the social media coverage as well as press coverage from ADA continue to be positive and Ray will speak to that in a moment. I just want to share with you a quick snapshot that I think is important and that looks at the claims and the enrollment. So this is what we see on a daily basis. This is for the week ending 8/5, which would have been last week. And you see here that a relatively stable number in the green line on the claims that were happening, which basically means we weren’t really promoting our copay program. We didn’t have any means to promote it, besides putting on our website. The bottom line is enrollment and that’s really our reps out there highlighting that it’s available on the web as well as we’re raising some awareness on the social media around this. And you saw following the week of July 22, July 29 and 8/5, we continued to see an increase in enrollments week over week and doubling really over the last four weeks. That’s the earliest indicator you could have because we know there’s about 1 to 2 week lag from the time a patient gets enrollment to the time to get to prescription filled and approved And you can see that in the top line when you look from 57 to 69 to 80, the prescription trends are moving in the right direction. And again, this will be the earliest indicator that we look at in addition to the new RX and trialist to happen on a weekly basis. So we’re excited, we’re seeing the support amongst the physicians, the reps are getting out there, they’re making the calls and we’re being welcome. Obviously it’s sometimes longer in some territories than others depending on academics versus private practice. But so far, early indicators are very positive from the customers. With that said, I’ll now turn it over to Ray.
